Presence of Sst5TMD4, a Truncated Splice Variant of the Somatostatin Receptor Subtype 5, Is Associated to Features of Increased Aggressiveness in Pancreatic Neuroendocrine Tumors

Oncotarget - United States
doi 10.18632/oncotarget.6565
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Somatostatin Receptor Endoradiotherapy of Neuroendocrine Tumors: Experience in Hungarian Patients

Orvosi Hetilap
Medicine
2011English

Therapeutic Targeting of Tumor-Associated Macrophages in Pancreatic Neuroendocrine Tumors

International Journal of Cancer
Cancer ResearchOncology
2018English

Expression of Transcription Factors in MEN1-associated Pancreatic Neuroendocrine Tumors

Endocrinology, Diabetes and Metabolism Case Reports
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2015English

Prediction of the Aggressiveness of Non-Functional Pancreatic Neuroendocrine Tumors Based on the Dual-Tracer PET/CT

EJNMMI Research
Nuclear MedicineRadiologyImaging
2019English

Pancreatic Neuroendocrine Tumors

Revista Espanola de Enfermedades Digestivas
MedicineGastroenterology
2017English

Implication of Filamin a in Pulmonary Neuroendocrine Tumors Aggressiveness and Progression

Endocrine Abstracts
2016English

Molecular Pathogenesis of Pancreatic Neuroendocrine Tumors

Cancers
Cancer ResearchOncology
2010English

Regional Lymphadenectomy Is Indicated in the Surgical Treatment of Pancreatic Neuroendocrine Tumors (PNETs)

Annals of Surgery
Surgery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy